These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37273950)

  • 21. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.
    Alhossan A; Lee CS; MacDonald K; Abraham I
    J Allergy Clin Immunol Pract; 2017; 5(5):1362-1370.e2. PubMed ID: 28351783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting.
    Braunstahl GJ; Chlumský J; Peachey G; Chen CW
    Allergy Asthma Clin Immunol; 2013 Dec; 9(1):47. PubMed ID: 24305549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry.
    Hutyrová B; Bystroň J;
    Postepy Dermatol Alergol; 2018 Oct; 35(5):510-515. PubMed ID: 30429711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
    Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
    Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
    Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
    Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.
    MacDonald KM; Kavati A; Ortiz B; Alhossan A; Lee CS; Abraham I
    Expert Rev Clin Immunol; 2019 May; 15(5):553-569. PubMed ID: 30763137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.
    Hanania NA; Niven R; Chanez P; Antoine D; Pfister P; Garcia Conde L; Jaumont X
    World Allergy Organ J; 2022 Oct; 15(10):100695. PubMed ID: 36254180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
    Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
    J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.
    Llanos JP; Bell CF; Packnett E; Thiel E; Irwin DE; Hahn B; Ortega H
    J Asthma Allergy; 2019; 12():43-58. PubMed ID: 30774390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: A post-marketing surveillance.
    Asano K; Sumi K; Yoshisue H; Nakamura N; Nagasaki M; Sasajima T; Matsumoto H
    Pulm Pharmacol Ther; 2020 Oct; 64():101950. PubMed ID: 32950661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
    Rojo-Tolosa S; González-Gutiérrez MV; Sánchez-Martínez JA; Jiménez-Gálvez G; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
    Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.
    Braunstahl GJ; Canvin J; Peachey G; Chen CW; Georgiou P
    Biol Ther; 2014 Dec; 4(1-2):57-67. PubMed ID: 25371373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.